Hereditary Transthyretin Amyloidosis Market Report 2025

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to factors such as the rising incidence of hereditary transthyretin amyloidosis, increased research and development activities, a growing number of cardiac amyloidosis cases, heightened disease awareness, and improvements in healthcare infrastructure.

The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be attributed to factors such as the increasing geriatric population, rising disposable incomes, a higher incidence of hereditary transthyretin amyloidosis, growth in the development of new drugs, and advancements in genetic testing. Key trends in the forecast period include the development of advanced treatment products, improvements in diagnostic techniques, progress in drug development, rising demand for effective therapies, and advancements in medical technology.

The increasing geriatric population is expected to drive the growth of the hereditary transthyretin amyloidosis market. This population, defined as individuals aged 65 and older, often requires specialized healthcare due to the aging process. The growth in this demographic is fueled by rising life expectancy, thanks to advancements in healthcare and living standards. Hereditary transthyretin amyloidosis (hATTR) particularly affects the elderly, causing progressive neuropathy and cardiomyopathy, which increases morbidity in older individuals. According to the Population Reference Bureau, the U.S. population aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. This growing geriatric population is contributing to the market's expansion.

Companies in the hereditary transthyretin amyloidosis market are developing cutting-edge therapeutics such as RNAi therapeutics to reduce the production of the transthyretin (TTR) protein. RNAi therapeutics use RNA interference technology to silence specific genes and reduce the production of proteins that cause diseases. For example, in October 2024, Alnylam Pharmaceuticals, Inc. submitted a supplemental new drug application (sNDA) to the U.S. FDA for Vutrisiran (AMVUTTRA) to treat transthyretin amyloidosis with cardiomyopathy. This RNAi therapy targets the TTR protein, a key player in the disease’s progression. Vutrisiran’s subcutaneous administration offers a more patient-friendly alternative to intravenous treatments, positioning it as a promising option for those affected by this severe condition.

In July 2023, Ionis Pharmaceuticals, Inc. entered into a partnership with AstraZeneca plc to co-develop and market eplontersen for treating transthyretin amyloidosis (ATTR) in the U.S. This collaboration also aims to enhance global access to the therapy by leveraging AstraZeneca’s broad commercial presence, particularly in Latin America and other international regions. AstraZeneca is a UK-based biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines.

Major players in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, and Autotac Bio Inc.

North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hereditary transthyretin amyloidosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hereditary transthyretin amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hereditary transthyretin amyloidosis (hATTR) is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in various organs. This condition primarily impacts the nervous system, heart, and other tissues, resulting in progressive neuropathy and cardiomyopathy.

The main treatment types for hereditary transthyretin amyloidosis include oral administration, subcutaneous injection, and other methods. Oral treatments, such as tablets, capsules, or liquids, provide a convenient and patient-friendly option, improving accessibility and adherence. The drug classes used in treating hATTR amyloidosis include RNAi agents such as patisiran and small interfering RNAs (siRNAs) such as vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and are used in settings such as hospitals, clinics, and other healthcare facilities.

The hereditary transthyretin amyloidosis market research report is one of a series of new reports that provides hereditary transthyretin amyloidosis market statistics, including the hereditary transthyretin amyloidosis industry global market size, regional shares, competitors with the hereditary transthyretin amyloidosis market share, detailed hereditary transthyretin amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. This hereditary transthyretin amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.